(Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025.
Dexcom's 2026 revenue estimates lagged analysts' expectations, according to data compiled by the London Stock Exchange Group (LSEG).
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q4 CY2025, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be ...
DexCom, Inc. DXCM reported fourth-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which beat the Zacks Consensus ...
DexCom reported worldwide revenue of $1.26 billion versus $1.11 billion a year earlier, marking 13% reported growth and 12% organic. U.S. Q4 revenue climbed 11% year over year to $892 million, while ...
St. John Neumann's Buckley, diagnosed with Type 1 diabetes at 8, navigates the daily challenges of managing his condition ...
SAN DIEGO (AP) — SAN DIEGO (AP) — DexCom Inc. (DXCM) on Thursday reported fourth-quarter earnings of $267.3 million. On a per-share basis, the San Diego-based company said it had profit of 68 cents.
Q4 2025 Earnings Call February 12, 2026 4:30 PM ESTCompany ParticipantsSean Christensen - Vice President of Finance and ...
5don MSN
“It’s like a personal sleep coach on your finger”: Oura Ring 4 vs Gen 3, tested for 6 months
Me 🤝 wearing my ring 24/7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results